Do all lung adenocarcinomas follow a stepwise progression?
Do all lung adenocarcinomas follow a stepwise progression?
复制标题
DOI：
10.1016/j.lungcan.2011.05.021
复制
发表时间：
2011-10
期刊：
影响因子：
5.3
通讯作者：
Powell, Charles A.
中科院分区：
文献类型：
--
作者：
Yatabe, Yasushi;Borczuk, Alain C.;Powell, Charles A.
与结直肠癌的腺瘤-癌序列相似，肺腺癌被认为遵循一个线性的多步骤进展，即先有病变进展为原位腺癌，然后是浸润性腺癌。然而，肺腺癌不再被认为是一种单一类型的肿瘤，而是一组不同的肿瘤亚群，它们来自不同的分子途径。与这一概念一致，最近的研究结果表明，这种线性进展可能不会发生在所有肺腺癌中。首先，根据基于表达谱的分子分类，肺癌至少可以分为两个亚集；癌前病变和原位病变具有分子表达和临床特征的特征，只有一个亚集，这表明线性级数只适用于分子分类中的亚集。其次，当根据进展步骤检测EGFR和KRAS时，KRAS的突变率是不成比例分布的；然而，根据进展模式，基因改变应该在整个进展过程中均匀累积。第三，通过比较基因组杂交分析，发现部分原位腺癌与侵袭性腺癌基因改变不连续。最后，有一些临床观察支持某些病变保留了进展。在这篇综述中，我们假设了肺腺癌进展的一种新的情况，它不支持线性进展模式。
Similar to the adenoma-carcinoma sequence of colorectal cancer, lung adenocarcinoma is thought to follow a linear multistep progression, in which a precursor lesion progresses to adenocarcinoma in situ, which is followed by invasive adenocarcinoma. However, lung adenocarcinoma can no longer be considered as a single type of tumor but rather a group of distinct subsets of tumors that arise from different molecular pathways. Consistent with this concept, recent findings revealed that this linear progression might not occur in all lung adenocarcinomas. First, according to the molecular classification based on expression profiling, lung cancer can be divided into at least two subsets; precancerous and in-situ lesions share characteristics of molecular expression and clinical features with only one of the two subsets, suggesting that the linear progression is only applicable to the subset in the molecular classification. Second, when EGFR and KRAS were examined based on the progression steps, the mutation rate of KRAS was disproportionally distributed; however, according to the progression schema, gene alterations should be evenly accumulated along the entire progression. Third, by means of comparative genomic hybridization analysis, some adenocarcinoma in situ revealed gene alterations discontinuous to invasive adenocarcinoma. Finally, there were some clinical observations that support that some lesions retain the progression. In this review, we hypothesize a novel scenario for the progression of lung adenocarcinoma, which does not support a linear progression schema.
登录
查看更多内容
影响因子：
3.5
作者：
Kurasono, Y;Ito, T;Kitamura, H
通讯作者：
Kitamura, H
非典型腺瘤增生与原发性肺癌之间的关联。
影响因子：
8.8
作者：
Chapman AD;Kerr KM
通讯作者：
Kerr KM
DOI：
10.1513/pats.200607-143jg
发表时间：
2007-01-01
期刊：
Proceedings of the American Thoracic Society
影响因子：
--
作者：
Borczuk, Alain C;Powell, Charles A
通讯作者：
Powell, Charles A
DOI：
10.1097/jto.0b013e318206a221
发表时间：
2011-02
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Travis WD;Brambilla E;Noguchi M;Nicholson AG;Geisinger KR;Yatabe Y;Beer DG;Powell CA;Riely GJ;Van Schil PE;Garg K;Austin JH;Asamura H;Rusch VW;Hirsch FR;Scagliotti G;Mitsudomi T;Huber RM;Ishikawa Y;Jett J;Sanchez-Cespedes M;Sculier JP;Takahashi T;Tsuboi M;Vansteenkiste J;Wistuba I;Yang PC;Aberle D;Brambilla C;Flieder D;Franklin W;Gazdar A;Gould M;Hasleton P;Henderson D;Johnson B;Johnson D;Kerr K;Kuriyama K;Lee JS;Miller VA;Petersen I;Roggli V;Rosell R;Saijo N;Thunnissen E;Tsao M;Yankelewitz D
通讯作者：
Yankelewitz D
影响因子：
8.8
作者：
Smith, AL;Hung, J;Walker, L;Rogers, TE;Vuitch, F;Lee, E;Gazdar, AF
通讯作者：
Gazdar, AF